DocumentRX-4313
Issued
Read3 min

FDA approves Livsayis for AChR-positive generalised myasthenia gravis

FDA approved Livsayis for AChR-positive generalised myasthenia gravis after a 2.3-point week-24 MG-ADL advantage over placebo in the Phase III NIMBLE trial.

TAG V-8328 · 561 words on the filing

FDA approves Regeneron’s Livsayis for generalised myasthenia gravis - Pharmaceutical Technology
FDA approves Regeneron’s Livsayis for generalised myasthenia gravis - Pharmaceutical Technologyfreegr / pixabay

Summary of findings

  • FDA approved Livsayis for adults with anti-AChR-positive generalised myasthenia gravis; dosing is four times annually.
  • Phase III NIMBLE showed a statistically significant 2.3-point week-24 MG-ADL advantage over placebo.
  • At week 24, 76.6% of treated patients achieved at least a 3-point MG-ADL improvement, versus 44.1% on placebo.
  • An EU regulatory decision is expected in late 2027, with filings planned in Japan and other territories.
  • Regeneron extended its nearly $270 million Inmazeb US Government contract through 2031.

The US Food and Drug Administration has approved Regeneron Pharmaceuticals’ Livsayis (cemdisiran) for adults with generalised myasthenia gravis who test positive for anti-acetylcholine receptor antibodies. The therapy is administered subcutaneously four times annually.

Livsayis is a small interfering RNA designed to decrease circulating complement component factor 5 protein levels and curb terminal complement activation. The approval also gives Regeneron its first approved medicine in neurology and its first approved siRNA therapy.

Which trial supported the approval?

Regeneron based the clearance on the ongoing randomised, double-blind, placebo-controlled Phase III NIMBLE study, NCT05070858. Participants were individuals with generalised myasthenia gravis who maintained discretionary background immunosuppressants.

The trial tested the therapy alongside participants’ maintained background treatment. Its reported efficacy window covers 24 weeks, although NIMBLE remains ongoing. Patients showed earlier functional gains within two weeks, ahead of the full comparative assessment.

How strong were the week-24 results?

Regeneron reported the 24-week dataset across two functional assessments and several responder thresholds.

  • MG-ADL mean change: recipients improved 4.5 points, versus 2.2 points with placebo; the 2.3-point difference was statistically significant.
  • At least a 3-point MG-ADL improvement: 76.6% of treated patients reached that threshold at week 24, compared with 44.1% on placebo.
  • Clinician-administered Quantitative Myasthenia Gravis assessment: treated patients improved 4.2 points, against 1.5 points for placebo, yielding an adjusted gain of 2.8 points.
  • At least a 5-point improvement: 48.4% of treated patients achieved the threshold, versus 19.0% receiving placebo.
  • Control over 24 weeks: symptom control continued throughout the period without diminished efficacy.

The 2.3-point MG-ADL difference was the comparison explicitly identified as statistically significant. Regeneron reported the 2.8-point QMG advantage as an adjusted gain, alongside 4.2-point and 1.5-point improvements for treatment and placebo.

Adverse reactions affecting at least 5% of patients included injection-site reactions, urinary tract infections and viral infections. Each of those three categories met the threshold Regeneron cited.

What did George Yancopoulos say?

Regeneron board co-chair, president and chief scientific officer George Yancopoulos said:

“Livsayis is Regeneron’s first approved medicine in neurology, and an important new option for people living with generalised myasthenia gravis who need effective disease control without a heavy treatment burden.

“As Regeneron’s first approved siRNA therapy, this approval marks a meaningful step forward for our neuroscience pipeline as we relentlessly pursue bold, new approaches to transform care for people living with serious neurological diseases.”

Yancopoulos tied the approval to two company milestones: its first approved neurology medicine and its first approved siRNA therapy. Both claims sit within his description of Regeneron’s neuroscience pipeline.

Who manages manufacturing and access?

Under a global agreement with Alnylam, Regeneron manages Livsayis manufacturing, commercialisation and clinical progression. The company also facilitates patient access and benefit verification through its myRARE programme.

Where do the next regulatory decisions stand?

European Union health authorities are reviewing Livsayis, with a decision expected during late 2027. Regeneron plans submissions in additional territories, including Japan. The European review and planned filings extend the product’s regulatory programme beyond the US approval.

Which other Regeneron contract was extended?

Separately, Regeneron agreed last month to a nearly $270 million contract extension to supply Inmazeb, its Ebola therapy, to the US Government. The revised supply commitment runs through 2031.

via FDA industry wire (Google News) (Source)

Share this article:

More from Marcus Bennett

Marcus Bennett

Show full bio

News editor covering regulation, policy and their impact on global pharmaceutical industry at PharmInsider.

10 articles

Linked filings

  1. C-7292
  2. K-7275
  3. K-8685
  4. E-2578
  5. K-2547

« Previous filingNext filing »